Brief: Abeona Therapeutics And Beacon Therapeutics Announce Non-Exclusive Agreement For Beacon To Evaluate Therapeutic Potential Of Abeona's Patented AAV204 Capsid For Select Ophthalmology Indications

Abeona Therapeutics

11/07/2024 13:02

July 11 (Reuters) - Abeona Therapeutics Inc  ABEO.O :
    * ABEONA THERAPEUTICS AND BEACON THERAPEUTICS ANNOUNCE
NON-EXCLUSIVE AGREEMENT FOR BEACON TO EVALUATE THERAPEUTIC
POTENTIAL OF ABEONA'S PATENTED AAV204 CAPSID FOR SELECT
OPHTHALMOLOGY INDICATIONS
    * ABEONA THERAPEUTICS: BEACON TO HAVE RIGHT TO EVALUATE, FOR
12-MONTH PERIOD, AAV204 CAPSID FOR POTENTIAL USE IN CERTAIN
OPHTHALMOLOGY INDICATIONS
    * ABEONA THERAPEUTICS: BEACON TO HAVE RIGHT TO USE AAV204
FOR UP
TO 4 ADDITIONAL NOMINATED GENE OR DISEASE TARGETS SUBJECT TO
CERTAIN CONDITIONS
    * ABEONA THERAPEUTICS: TO GET UPFRONT PAYMENT UPON BEACON'S
EXERCISE OF OPTION TO LICENSE AAV204, WITH EXTRA PAYMENTS ON
ACHIEVEMENT OF MILESTONES

Source text for Eikon:  ID:nGNX23T5Qx 
Further company coverage:  ABEO.O 

 ((Reuters.Briefs@thomsonreuters.com;))